周一盘中，德国生物科技公司BioNTech SE（BNTX）股价大幅下跌7.73%，引发市场广泛关注。此次股价大跌主要受到美国食品和药物管理局（FDA）疫苗高级官员Peter Marks辞职的报道影响。
据报道，FDA疫苗和生物制品评估研究中心主任Peter Marks计划辞职。作为FDA内部疫苗审批的关键人物，Marks的离职可能对疫苗审批流程和标准产生重大影响，这引发了投资者对疫苗公司未来发展前景的担忧。
BioNTech作为新冠疫苗的主要研发和生产商之一，其股价对这一消息表现得尤为敏感。分析人士指出，FDA高层的变动可能会影响到未来疫苗的审批进程和政策导向，从而对BioNTech等疫苗制造商的业务发展带来不确定性。投资者正密切关注事态发展，以评估这一人事变动可能对疫苗行业产生的长期影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.